S&P Futures
4,162.00 +31.50 (+0.76%) Dow Futures
34,205.00 +210.00 (+0.62%) Nasdaq Futures
12,698.50 +153.25 (+1.22%) Russell 2000 Futures
1,964.30 +14.40 (+0.74%) Crude Oil
77.94 -0.53 (-0.68%) Gold
1,895.10 +4.40 (+0.23%)
Illumina, Inc. (ILMN)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 215.74 |
| Open | 209.27 |
| Bid | 200.01 x 1100 |
| Ask | 201.90 x 800 |
| Day's Range | 198.19 - 216.15 |
| 52 Week Range | 173.45 - 371.16 |
| Volume | |
| Avg. Volume | 1,212,222 |
| Market Cap | 31.224B |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | 46.38 |
| EPS (TTM) | 4.28 |
| Earnings Date | Feb 08, 2023 - Feb 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 253.47 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ILMN
Related Research
- Illumina, Inc.Analyst Report: Illumina, Inc.Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.RatingFair ValueEconomic MoatyesterdayMorningstar
- Investor's Business Daily
The Wild Card That Keeps Haunting DNA-Reading Giant Illumina
Illumina beat sales estimates, but profit came in light during the fourth quarter. That led ILMN stock to fall Wednesday.
- PR Newswire
Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system was recently delivered to the Broad Institute. Alex Aravanis, PhD, chief technology officer of Illumina, made the announcement today in a presentation at the Advances in Genome Biology and Technology (AGBT) conference in Hollywood, Florida. Aravanis also announced much anticipated updates on Illumina's innovation roadmap including Illumina Complete Lo
- Zacks
Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down
Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.
